A Microfluidic Droplet Array Promotes Trastuzumab Sensitivity Exploration of Single Breast Cancer Cells.

Small

Research Center for Analytical Sciences, Department of Chemistry, College of Sciences, Northeastern University, Shenyang, Liaoning, 110819, P. R. China.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Drug sensitivity is a major determinant influencing the efficiency of cancer treatment, and its evaluation faces critical challenges due to the cancer cell heterogeneity. Herein, a droplet-driven compartmentalization array (SCell chip) is presented to uncover single-cell trastuzumab sensitivity. Leveraging the differential flow resistance principle, the chip enables the flexible generation of single droplets orderly situated at designated spots. The single droplet includes parallel hydrodynamic microtraps empowers efficient compartments for single cell capture, and culture, and employs apt-functionalized microbeads to immune-affinity capture single cell extracellular vesicles (EVs). The pairing capture of single cells and their EVs using single beads allows simultaneous identification of EVs and their original cells. The protein profiles (HER2 and CD63) and anti-cancer drug challenge revealed the cellular/EVs secretion heterogeneity at the single cell level and cell susceptibility to trastuzumab, further confirming that this chip achieves discriminating and predicting single breast cancer cells with different trastuzumab sensitivity using single cell/EVs profiling strategy. Furthermore, this analysis process retains the cell viability of measured cells to promote downstream detection integration. Overall, the SCell chip offers new avenues for single-cell analysis and exhibits great potential for cancer diagnostic and targeted treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1002/smll.202410388DOI Listing

Publication Analysis

Top Keywords

trastuzumab sensitivity
12
single cell
12
single
10
single breast
8
breast cancer
8
cancer cells
8
scell chip
8
capture single
8
cell
6
cancer
5

Similar Publications

Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody-drug conjugate (ADC) with efficacy across adult cancers exhibiting variable HER2 expression. Prior studies demonstrating HER2 expression in osteosarcoma (OS) motivated a clinical trial of T-DXd in pediatric and adolescent/young adults with OS but was terminated early for inactivity. We evaluated the activity of T-DXd using OS patient-derived xenograft (PDX) models and found a 22% objective response rate despite no detectable HER2 expression across PDXs tested.

View Article and Find Full Text PDF

Mass cytometry with antibodies labelled with stable metal isotopes enables both sensitive imaging and the quantification of protein expression in biological samples. Typically, these specimens are exposed to a panel of labelled antibodies , after sample collection. Here, we have developed a rhodium-labelled immunoconjugate of the HER2-targeted therapeutic IgG1 antibody, trastuzumab, and evaluated its biodistribution using mass cytometry techniques.

View Article and Find Full Text PDF

m6A mRNA methylation initiated by METTL14 promotes STK11 translation and increases STK11 activity to induce anti-HER2 therapy resistance in breast cancer.

Biochim Biophys Acta Mol Basis Dis

August 2025

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine Nanjing Medical University Nanjing, China. Electronic address:

Resistance to HER2-targeted therapies presents a major challenge in the treatment of patients with HER2-positive breast cancer. N(6)-methyladenosine (m6A) modification plays a critical role in tumor progression; however, its role in mediating resistance to anti-HER2 therapy remains poorly defined. In trastuzumab-resistant HER2-positive breast cancer tissues, METTL14 expression is significantly upregulated and correlates with poor trastuzumab response.

View Article and Find Full Text PDF

The recent approval of antibody drug conjugates (ADCs) targeting HER2 (like Trastuzumab Deruxtecan or T-DXd) have led to challenges for the immunohistochemical (IHC) companion diagnostic test since the test was optimized for gene amplified levels of HER2. Here we develop and validate an objective test for low level HER2 expression toward more accurate selection of patients for T-DXd. We validated the high-sensitivity HER2 assay using a mix of the requirements for an IHC assay and that of a ligand binding assay.

View Article and Find Full Text PDF

To explore the application value of machine learning algorithms in constructing a predictive model for cardiovascular toxicity in breast cancer patients receiving anthracycline-based chemotherapy. This study was a retrospective cohort study. The female patients with breast cancer who received anthracyclines in the Affiliated Cancer Hospital of Xinjiang Medical University from January 2020 to December 2023 were enrolled.

View Article and Find Full Text PDF